ADAURA Update: Only the End of the Beginning
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Arriagada R, Auperin A, Burdett S, Higgins J, Johnson D, Le Chevalier T
. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010; 375(9722):1267-77.
PMC: 2853682.
DOI: 10.1016/S0140-6736(10)60059-1.
View
2.
Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S
. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for -mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021; 17(31):4045-4055.
PMC: 8530153.
DOI: 10.2217/fon-2021-0549.
View
3.
Majem M, Goldman J, John T, Grohe C, Laktionov K, Kim S
. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. Clin Cancer Res. 2022; 28(11):2286-2296.
PMC: 9359973.
DOI: 10.1158/1078-0432.CCR-21-3530.
View
4.
Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R
. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9.
DOI: 10.1200/JCO.2007.13.9030.
View
5.
Wu Y, Tsuboi M, He J, John T, Grohe C, Majem M
. Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18):1711-1723.
DOI: 10.1056/NEJMoa2027071.
View